Skip to content

Leukine

DRUG9 trials

Sponsors

Vestre Viken HF, Oslo University Hospital Hf, Greenwich LifeSciences Inc., Y-mAbs Therapeutics A/S, Brenus Pharma

Conditions

Critical IllnessHereditary Pulmonary Alveolar ProteinosisImmuno-suppressionMalignant pleural mesothelioma (MPM)Ovarian cancerRenal Cell CarcinomaSepsisTreatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow

Phase 1

Phase 2

Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma
WithdrawnNCT00176280
University of KentuckyRenal Cell Carcinoma
Start: 2005-09-30Updated: 2015-06-18
Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
CompletedNCT01511068
Children's Hospital Medical Center, CincinnatiHereditary Pulmonary Alveolar Proteinosis
Start: 2012-08-31End: 2014-07-31Updated: 2023-08-30
Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)
Active, not recruitingCTIS2022-502604-67-00
Oslo University Hospital HfMalignant pleural mesothelioma (MPM)
Start: 2019-12-20Target: 90Updated: 2025-04-03
A randomized, phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer
CompletedCTIS2022-502437-25-00
Vestre Viken HFadvanced or metastatic non-small cell lung cancer
Start: 2022-08-15End: 2024-09-12Target: 141Updated: 2024-12-04
A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RecruitingCTIS2023-508587-29-00
Y-mAbs Therapeutics A/STreatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow
Start: 2018-04-03Target: 81Updated: 2025-11-04
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer.
Not yet recruitingCTIS2024-516327-14-00
Nordic Society Of Gynaecological Oncology Clinical Trial UnitOvarian cancer
Target: 188Updated: 2025-10-02

Phase 3